Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities

被引：37

作者：

Hagan, H

Latka, MH

Campbell, JV

Golub, ET

Garfein, RS

Thomas, DA

Kapadia, F

Strathdee, SA

机构：

[1] Natl Dev Inst, Ctr Drug Use & HIV Res, New York, NY 10010 USA

[2] Nat Res Inst, Ctr Drug Use & HIV Res, New York, NY 10010 USA

[3] New York Acad Med, Ctr Urban Epidemiol Studies, New York, NY USA

[4] Publ Hlth Seattle & King Cty, HIV AIDS Epidemiol, Seattle, WA USA

[5] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA

[6] Sch Med, Baltimore, MD USA

[7] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2006年 / 42卷 / 05期

关键词：

D O I：

10.1086/499951

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Among 404 injection drug users aged 18-35 who tested positive for hepatitis C virus (HCV) RNA, 96% had conditions that are potentially unwarranted contraindications for HCV treatment ( e. g., problem drinking, moderate-to-severe depression, and recent drug injection). Restrictive eligibility criteria may deny treatment to a large proportion of patients who could benefit from it.

引用

页码：669 / 672

页数：4

共 22 条

[1] AN INVENTORY FOR MEASURING DEPRESSION
BECK, AT
ERBAUGH, J
WARD, CH
MOCK, J
MENDELSOHN, M
[J]. ARCHIVES OF GENERAL PSYCHIATRY, 1961, 4 (06) : 561 - &
[2] Sex related HIV risk behaviors: differential risks among injection drug users, crack smokers, and injection drug users who smoke crack
Booth, RE
Kwiatkowski, CF
Chitwood, DD
[J]. DRUG AND ALCOHOL DEPENDENCE, 2000, 58 (03) : 219 - 226
[3] Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C:: a randomized controlled trial
Bruno, S
Cammà, C
Di Marco, V
Rumi, M
Vinci, M
Camozzi, M
Rebucci, C
Di Bona, D
Colombo, M
Craxì, A
Mondelli, MU
Pinzello, G
[J]. JOURNAL OF HEPATOLOGY, 2004, 41 (03) : 474 - 481
[4] Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
Edlin, BR
Seal, KH
Lorvick, J
Kral, AH
Ciccarone, DH
Moore, LD
Lo, B
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) : 211 - 214
[5] Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: Low eligibility for interferon treatment
Fleming, CA
Craven, DE
Thornton, D
Tumilty, S
Nunes, D
[J]. CLINICAL INFECTIOUS DISEASES, 2003, 36 (01) : 97 - 100
[6] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried, MW
Shiffman, ML
Reddy, KR
Smith, C
Marinos, G
Goncales, FL
Haussinger, D
Diago, M
Carosi, G
Dhumeaux, D
Craxi, A
Lin, A
Hoffman, J
Yu, J
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 975 - 982
[7] Screening for depressive symptoms among HCV-infected injection drug users: Examination of the utility of the CES-D and the beck depression inventory
Golub, ET
Latka, M
Hagan, H
Havens, JR
Hudson, SM
Kapadia, F
Campbell, JV
Garfein, RS
Thomas, DL
Strathdee, SA
[J]. JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE, 2004, 81 (02): : 278 - 290
[8] Neuropsychiatric side effects of HCV therapy and their treatment:: focus on IFNα-induced depression
Hauser, P
[J]. GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2004, 33 (01) : S37 - +
[9] Hepatitis C infection and injection drug use: The role of hepatologists in evolving treatment efforts
Kresina, TF
Seeff, LB
Francis, H
[J]. HEPATOLOGY, 2004, 40 (03) : 516 - 519
[10] Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels
Kronenberger, B
Herrmann, E
Micol, F
von Wagner, M
Zeuzem, S
[J]. HEPATOLOGY, 2004, 40 (06) : 1442 - 1449

← 1 2 3 →